Fusing innovation and biotech for a more progressive tomorrow

See The Bigger Picture in Immuno Oncology Clinical Trials

Our advanced 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products are aimed to enable physicians to See The Bigger Picture, and accelerate the progress of immunotherapy around the world. Join us as we reimagine a new vision and approach towards immuno oncology patient care paths. Explore more about who we are, how we innovate for tomorrow and why partnering with us will help to challenge, create and transform patient care.

Our Technology

CD8 ImmunoPET imaging technology

CD8 ImmunoPET imaging technology

Our technology uses ‘minibody’ antibodies to scan patients head-to-toe, delivering an in-depth visual profile of immunity status, before, during and after treatment.

Discover CD8 ImmunoPET
Target RPT platform

Target RPT platform

Using our minibody and cys-diabodies platform technologies we are generating best in class RPT solutions, to kill tumor cells with targeted radiation.

Discover RPT

Tomorrow’s cancer patient care paths begin here…

PET Imaging

Phase 1
Phase 2
Phase 3
PET imaging of CD8 Cells in Oncology (89Zr crefmirlimab berdoxam)
PET imaging CD8 T-cells in Inclusion Body Myositis (89Zr crefmirlimab berdoxam)
PET Imaging CD4 T-cells trafficking in Oncology and Autoimmune diseases (89Zr-Df-IAB41M2C)

Radiopharmaceutical Therapy (RPT)

Lead Selection
IND Enabling Studies
Clinical Studies
PSMA / Prostate Cancer
Integrin αvβ6 / Solid Tumors
DLL3 / Small-Cell Lung Cancer
Undisclosed / Solid Tumors
Undisclosed / Ovarian Cancer

Optical Imaging

Phase 1
Phase 2
Phase 3
PSMA optical imaging: Prostate Cancer (IR800-IAB2MA)
PSMA optical imaging: Renal Cancer (IR800-IAB2MA)

Discover our pipeline of next generation biotech innovations.


Meet the team striving to create, challenge and transform the future of immuno oncology patient care paths.

At ImaginAb, everything we do is underpinned by medical expertise and scientific innovation. And our people are paramount to that.

Meet the team

Join us to reimagine the future of immuno oncology.